The chemokine receptor CCR2 is central for migration of certain populations of monocytes and T cells into sites of inflammation. We report the discovery of a novel small molecule, CCX140-B, that is an orally bioavailable, selective and potent antagonist of human CCR2. CCX140-B inhibited CCR2-mediated Ca transgenic mice. Unlike other CCR2 antagonists, CCX140-B had no effect on plasma CCL2 levels or blood monocyte numbers in mice. In two Phase 1 clinical trials, CCX140-B was administered to healthy human volunteers and found to be well tolerated and to have a linear pharmacokinetic profile with a T 1/2 of 48 -60 hours. Similar to the findings in mice, there were no effects on plasma CCL2 levels or blood monocyte numbers. This study identifies the doses required to effectively block CCR2 on blood monocytes and has informed the doses selected in various ongoing Phase 2 clinical trials.
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Introduction
The movement of cells throughout the body under homeostatic and inflammatory conditions is exquisitely orchestrated by the actions of chemokines and chemokine receptors (Charo and Ransohoff, 2006; Viola and Luster, 2008) . C-C Chemokine receptor 2 (CCR2) is primarily expressed on monocytes in the circulation, although expression can also be seen on certain T cell populations and possibly on non-immune cells such as adipocytes and podocytes. CCR2 has four known ligands, CCL2 (MCP-1), CCL8 (MCP-2), CCL7 (MCP-3), and CCL13 (MCP-4). CCL2 is the most selective of these chemokines for CCR2 and thus has been the most broadly studied CCR2 ligand.
CCR2 has been implicated in the pathogenesis of type 2 diabetes (T2D) and its associated co-morbidities, particularly diabetic nephropathy and neuropathy. For decades, the presence of systemic markers of inflammation has been known to increase with obesity.
The adipose tissue has been shown to produce multiple inflammatory cytokines, including TNFα, IL-6, and CCL2, expression levels of which correlate with the degree of adiposity (reviewed in Ferrante, 2007) . Several of these mediators have been shown to impair insulin sensitivity. For example, CCL2 impairs insulin-stimulated glucose uptake in human adipocytes and skeletal muscle cells, providing a link between inflamed adipose tissue and insulin resistance (Sell et al., 2006; Sartipy et al., 2003) . CCL2 is overexpressed in obese rodents (Sartipy et al.; , Takahashi et al., 2003 as well as obese humans (Christiansen et al., 2005; Kim et al., 2006) . Different depots of adipose tissue, such as visceral, subcutaneous, and epicardial adipose tissues, show increased expression of CCL2 in obese patients (Bruun et al., 2005; Malavazos et al., 2005) . A JPET #190918 clinical study identified elevated CCL2 levels in cardiac surgery patients as a risk factor for post-operative insulin resistance (Kremen et al., 2006) .
Other studies have defined adipose tissue macrophages as the primary source of proinflammatory mediators (Wellen and Hotamisligil, 2003) . In fact, the number of adipose tissue macrophages increases with increasing adiposity (Weisberg et al., 2003) .
Macrophage number in adipose tissue is dynamic and weight loss or gain rapidly changes the macrophage content of adipose tissue (Cancello et al., 2005) . Studies using rodent models of insulin resistance and Type 2 diabetes have indicated that the CCR2:CCL2 axis is a primary control point for the entry of inflammatory macrophages into the adipose tissue of obese subjects (Neels and Olefsky, 2006) . CCR2-deficient mice have reduced macrophage numbers in adipose tissue depots and display significantly improved metabolic parameters relative to wild-type counterparts (Weisberg et al., 2006) .
Here we present data detailing the preclinical and clinical characterization of CCX140-B, a novel small molecule antagonist of CCR2 (Basak et al., 2008) , for which evidence of clinical efficacy in type 2 diabetes has been recently disclosed (Hanefeld et al., 2011) . Its effects on CCR2-mediated functional endpoints, under fully physiological conditions, have been fully characterized in vitro. We also describe the therapeutic benefit of this compound in a mouse model of obesity-driven hyperglycemia and insulin resistance. In addition, we describe key aspects of the Phase 1 clinical evaluation of CCX140-B in healthy human volunteers. In vitro assays. Chemotaxis, calcium mobilization, and radioligand binding assays were conducted as previously described (Walters et al., 2010) .
Data analysis.
Inhibition values (IC 50 ) were calculated using non-linear regression with a one-site competition model (GraphPad Prism, GraphPad Software, La Jolla, CA). A 2 values for assessment of potency in chemotaxis assays were calculated from the following equation:
where A reflects the potency of the agonist in the absence of the antagonist and A' reflects the potency of the agonist in the presence of antagonist at a given concentration (M).
Effects of CCX140-B in the thioglycollate induced mouse model of sterile peritonitis
In this study, CCX140-B was formulated as a solution in 1% hydroxypropyl methylcellulose ® (Sigma-Aldrich, St Louis, USA) at drug concentrations of 0.3 mg/mL, 1 mg/mL or 3 mg/mL, for the 3 mg/kg, 10 mg/kg or 30 mg/kg doses. Mice were dosed orally (PO) twice daily for the duration of the study. Dosing began 1 hour prior to thioglycollate challenge. Mice were challenged intra-peritoneally (IP) with thioglycollate on day 0. Peritoneal macrophages were harvested 3 days after thioglycollate challenge by lavage with 5 mL of ice cold phosphate buffered saline (PBS).
q.d., and 10 mg q.d. Subjects in the 0.6 mg and 2 mg q.d. cohorts (n=6) were randomized to CCX140-B (n=5) or placebo (n=1) daily for 7 days. Subjects in the 5 mg and 10 mg q.d. cohorts (n=10) were randomized to CCX140-B (n=8) or placebo (n=2) daily for 10 days.
All subjects in both studies were in good general health prior to enrolling in the study and gave written Informed Consent to participate in the studies prior to any study procedures being performed. Study protocols were approved by the Ethics Committee of the Two Basels and by Swissmedic (Switzerland). The studies were conducted at Covance (Basel, Switzerland) in accordance with the Declaration of Helsinki, and Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines.
Safety and tolerability assessments. Standard clinical methods were used, including physical examinations, vital signs, 12-lead ECG, and clinical laboratory measurements, throughout both studies. Adverse events were recorded for the entire study duration.
Investigators assessed all adverse events for severity, duration, outcome, and possible relationship to study medication.
Pharmacokinetic assessment. Plasma samples were collected at predetermined timepoints.
Blood samples (8 mL) were collected into EDTA tubes, gently mixed and kept on wet ice until centrifuged (within 30-min) at 2,000 g, in a refrigerated centrifuge, for 10 min.
Resulting plasma was stored (-80 °C) until analysis. Following protein precipitation, supernatant solutions were analyzed by HPLC-MS/MS using a validated method (nominal plasma concentration range: 1-1,000 ng/mL). PK values were generated using Figure 1A ). In order to test the potency of CCX140-B under more physiologically relevant conditions, the THP-1 chemotaxis assay was run in the presence of 4.5% human serum albumin. Under these conditions, CCX140-B inhibited the CCL2-induced THP-1 chemotaxis with and IC 50 of 300 nM (n=30, Figure 1B ). In chronic inflammatory disorders, the levels of α1-acid glycoprotein (AAG) become elevated (Nakamura et al., 1993) . This acute phase protein has been shown to increase the non- Figure 1C ). The ability of CCX140-B to directly compete with [ 125 I]-CCL2 binding to human CCR2 was tested using stably transfected HEK293-CCR2B cells; in this assay, CCX140-B displayed an IC 50 of 7 nM (n=107, Figure 1D ).
Stimulation of THP-1 cells with CCL2 results in release of Ca 2+ from intracellular stores.
CCX140-B inhibited CCL2-induced calcium mobilization with an IC 50 value of 10 nM (n=4; Figure 1E ).
CCX140-B inhibits CCL2-induced chemotaxis, calcium mobilization and radioligand binding in primary human monocytes
Assessment of compound activity on primary cells and under physiologically relevant conditions (i.e., serum or blood) is an important part of the characterization of potential drugs (Walters et al., 2010; Dairaghi et al., 2011; Schall and Proudfoot, 2011) . CCR2 is primarily expressed on the monocytic cell population in blood, particularly in the CD14+ compartment. CCL2 induces chemotaxis of CD14+ primary monocytes with an EC 50 of 0.1-0.5 nM (data not shown). CCX140-B is a potent inhibitor of CCL2-induced monocyte chemotaxis with an IC 50 of 8 nM (n=2, Figure 2A ). In order to test the potency of CCX140-B under more physiologically relevant conditions, the monocyte chemotaxis assay was run in the presence of 100% human AB serum. Under these conditions Figure 2D ).
In order to gain a more clear understanding of the affinity of CCX140 for CCR2, saturation binding was performed using [ 3 H]-CCX140 on primary CD14+ human monocytes. This study indicated that CCX140 has an average K d of 2.3 nM towards human CCR2 (n=2, Figure 2E ).
CCX140-B inhibits chemotaxis induced by all CCR2 ligands in primary monocytes
It is important to assess the efficacy of any CCR2 antagonist against all known CCR2-activating chemokines, which in man includes four proteins: CCL2 (MCP-1), CCL7 blockade. At higher concentrations of CCX140-B (e.g., 10 µM) the chemokine dose response curves continued to shift to the right (~30-100 fold shifts) for CCL2, CCL7, and CCL13). Interestingly, the CCL8 dose response did not continue to right shift to the same extent, perhaps reflecting the selectivity of CCX140-B for CCR2, as CCL8 can also signal through CCR1, which is also expressed on blood monocytes. 
Preclinical pharmacokinetic profile of CCX140-B
The pharmacokinetic behavior of CCX140-B was tested in mouse, rat, and dog (Table 1) .
CCX140-B showed excellent oral bioavailability in all preclinical species tested. Plasma clearance values were also low across species, with dogs showing very low clearance rates. CCX140-B displays high exposure in all species at relatively low nominal doses and it appears to be primarily restricted to the blood compartment, as illustrated by its low volume of distribution.
Selectivity profile of CCX140-B against a broad panel of chemokine receptors and CYP enzymes
A broad panel of chemokine receptor selectivity was undertaken using both radioligand binding and chemotaxis assays. CCX140-B did not show any significant inhibition of any of the receptors tested (Table 2 ). CCX140-B was also tested at 10 μ M against the major CYP isoforms and was found to lack any inhibitory activity in enzymatic assays (Table 2) . Assessment of inhibition of the hERG potassium channel activity by patch clamp technique showed that CCX140-B lacked inhibition of hERG at concentrations up to 100 μ M (Table 2 ). CCX140-B was evaluated at 10 μ M in screens for interaction with 142 various biologically important receptors and found to lack activity against any of them (Supplemental Table 1 ).
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Characterization of human CCR2 knock-in (hCCR2 KI) mice
Due to the fact that CCX140-B does not bind with high affinity to mouse CCR2, transgenic mice were generated by homologous recombination which express human CCR2 under the control of endogenous genetic elements (hCCR2 KI mice). As shown in Figure 4A , the entire mouse CCR2 coding region was replaced with the human CCR2 coding region, while the endogenous mouse CCR2 control elements remain intact.
Following recombination, the neomycin resistance gene, which was flanked by loxP sites, was removed via Cre-mediated recombination. After generating the hCCR2 KI mice, it was important to characterize their monocyte inflammatory response. Mice were challenged with thioglycollate in a sterile peritonitis model and the recruitment of leukocytes into the peritoneal space was assessed 3 days after challenge. CCR2-/-mice displayed a characteristic reduction in total peritoneal leukocyte numbers after challenge, while the hCCR2 KI mice exhibited a response equal to wild-type mice ( Figure 4B ).
Activity of CCX140-B in hCCR2 KI mice
Having established that the hCCR2 KI mice displayed normal monocyte populations and responses to CCR2 ligands, pharmacology experiments were undertaken to determine the activity of CCX140-B in vivo. CCX140-B displays high selectivity for human CCR2 as there is strong inhibition of hCCR2 KI mouse bone marrow derived monocyte chemotaxis induced by mJE (mouse CCL2) ( Figure 5A ) but no inhibition of similar cells from wild-type control mice ( Figure 5B ). In concordance with the in vitro results, CCX140-B significantly reduces the peritoneal accumulation of macrophages in hCCR2 KI mice following thioglycollate challenge ( Figure 5C ) but has no effects on the influx of cells into the peritoneal space of wild type control mice ( Figure 5D ). CCX140-B (10 This article has not been copyedited and formatted. The final version may differ from this version. altering the systemic levels of mouse JE (CCL2) ( Figure 5F ).
CCX140-B improves insulin sensitivity in obese, diabetic hCCR2 KI mice
In order to study the effect of CCX140-B on hyperglycemia and insulin resistance in a mouse model of Type 2 diabetes, male hCCR2 KI mice were placed on a high fat diet at 6 weeks of age. The high fat diet delivered 60% of caloric content in the form of fat, while control diet mice received a diet with 10% of the caloric content derived from fat.
Mice were randomized to CCX140-B treatment or vehicle when fasting blood glucose levels exceeded 180 mg/dL, typically after 24-26 weeks on high fat diet. Two weeks of CCX140-B treatment significantly reduced both fasting glucose levels ( Figure 6A . Similarly to the findings in the thioglycollate studies, CCX140-B improved the diabetic condition of these mice with no change in systemic CCL2 levels ( Figure 6E ).
CCX140-B exerted all beneficial effect without altering body weight in any experimental
animals (data not shown).
Pharmacokinetic profile of CCX140-B in healthy human volunteers
CCX140-B was well tolerated and displayed a linear dose-exposure profile at all doses (0.05-10 mg) in the single-ascending-dose Phase-1 study ( Figure 7A ). Average CCX140 plasma levels above 1,000 ng/mL (~2 uM) were reached in this study and the plasma half-life of CCX140 approached 48 hours at the 10 mg dose. Following 10 days of 10 mg CCX140-B (Fig. 7B) , steady-state CCX140 plasma levels fluctuated from a peak of 2,800 ± 440 ng/mL (~5,600 ± 880 nM), achieved 2 hours post-dose, to a trough level of 1,770 ± 232 ng/mL (~3,500 ± 460 nM). Repeated dosing of CCX140-B did not result in changes to circulating monocyte numbers at either the 5 or 10 mg doses ( Figure 7C ). No increases in plasma levels of CCL2 were observed after CCX140-B administration ( Figure 7D ). The lack of effect of CCX140-B on both monocyte numbers as well as of a developmental defect in monocyte function but that CCR2 is the key driver of peripheral monocyte recruitment into the peritoneum following thioglycollate challenge.
The role of inflammation in obesity and type 2 diabetes has become clearer in recent years (Olefsky and Glass, 2010) . Monocytes are found in increasing numbers in adipose and hepatic tissues of insulin resistant and obese humans, and this observation is faithfully reproduced in rodent models of type 2 diabetes (Weisberg et al., 2003 , Cancello et al., 2005 . CCR2 has been implicated as the major chemokine receptor responsible for the accumulation of monocytes in peripheral tissues of obese, diabetic rodents and this reduced monocyte accumulation correlates with improvements in systemic glucose tolerance (Weisberg et al., 2006 , Tamura et al., 2008 , Yang et al., 2009 , Kang et al., 2010 ). Here we show that inhibition of CCR2 by CCX140-B significantly improves fasting plasma glucose levels in obese, diabetic hCCR2-KI mice. This benefit is rapid, as can occur with no systemic rise in CCL2 levels. Additionally, the administration of clinically relevant doses of CCX140-B to healthy human volunteers results in no alterations in systemic CCL2 levels, even after repeated dosing out to 10 days. Plasma levels achieved in this study exceeded the serum A 2 potency of the drug by 30 fold. In fact, there were no elevations seen in any of the CCR2 ligands in these healthy subjects.
These results clearly show that robust inhibition of CCR2 function can occur without elevations in ligand levels and may be a desirable feature of a CCR2 receptor antagonist.
The unique pharmacology responsible for the lack of CCL2 elevation or the lack of effects on monocyte numbers after CCX140-B administration is an area of active research in our laboratories. Some of the possibilities that are being addressed include the following: greater CCR2 selectivity of CCX140-B relative to other agents which also inhibit CCR5 to a great extent; unique binding kinetics to albumin and CCR2 when present in blood; some of the unwanted effects produced by other compounds result from a greater degree of inhibition of CCL8 (MCP-3) relative to CCX140-B; differences This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
